GlyTherix
  • Home
  • Company
  • Product Pipeline
  • For Investors
  • News
  • Contact Us
Select Page
GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence

GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence

by GlyTherix | May 24, 2023

Learn more about our Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells. The evidence for GPC-1 being a key target in cancer therapy continues to expand rapidly. This includes recent publications with our...
GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

by GlyTherix | Sep 8, 2022

GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

by GlyTherix | Jul 16, 2020

16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix  Technology

Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology

by GlyTherix | May 19, 2020

Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...

Recent Posts

  • GlyTherix Ltd Announces Cyclowest Holdings as Cornerstone Investor and exclusive Manufacturing, Supply & Distribution partner for 89Zirconium
  • Key GlyTherix patent finalises in-country registration journey
  • GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence

RECENT POSTS

  • GlyTherix Ltd Announces Cyclowest Holdings as Cornerstone Investor and exclusive Manufacturing, Supply & Distribution partner for 89Zirconium
  • Key GlyTherix patent finalises in-country registration journey
  • GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence
  • GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO

ENQUIRIES

Address
Level 1, 3 Innovation Road,
Macquarie Park NSW 2113, Australia

Australian Business Number
66 621 291 996

MORE INFO

FOR SHAREHOLDERS:
Shareholder Communications Options

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2023 | GLYTHERIX - ALL RIGHTS RESERVED